Account
Articles
08.01.2020
Greater access to medicines in the UK

NHS England is developing a new Commercial Framework, outlining potential opportunities for commerci...

Read more
Articles
04.09.2019
Gene therapies and Managed Entry Agreements

Zolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...

Read more
Articles
31.07.2019
Commercial patient access scheme

In England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...

Read more
Case Study
21.02.2019
MEA Training Workshop

Enhancing Managed Entry Agreement capabilities through interactive workshops.

Read more
Articles
13.11.2017
NICE's Modified Cancer Drugs Fund Process

This study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...

Read more
News
26.04.2017
PMA Perspective Q1 2017

Included in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...

Read more
Articles
05.03.2017
Managed entry agreements

MEAs are also known by other names such as risk-sharing agreements, value-added services, and result...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.